Federal Register Notice: FDA’s Psychopharmacologic Drugs Advisory Committee will meet 10/25, from 8 a.m. to 5 p.m. and 10/26, from 8 a.m. to 3 p.m. at the Hilton, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD. On 10/25, the committee will discuss proposed drug treatments for chronic psychiatric disorders and the need for longer-term efficacy data and optimal study designs for obtaining valid information about longer-term benefits of drug treatment. On 10/26, the committee will discuss the question of whether or not dietary restrictions would be needed for the 20 mg dose for Somerset Pharmaceuticals’ NDAs Emsam (selegiline transdermal system) (for both a short-term claim and a longer-term claim) for treating major depressive disorder. Contact Karen Templeton-Somers, (301)-827-7001. To view this notice, click here.